Multimodal Tumor Modeling With Post-Mortem Tissue for Diverse Drug Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clinical trials for cancer therapeutics often fail to represent the general population due to restrictive eligibility criteria, leading to marginalization of disadvantaged populations and limited effectiveness in diverse patient groups.
Innovation Solution
A method using post-mortem cancer patient tissue for analyzing cancer therapeutic candidates through in vitro, in silico, in vivo, and ex vivo models, allowing for a more diverse and high-throughput evaluation of therapeutic effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If restrictive eligibility criteria are used in clinical trials, then trial management and participant selection become easier, but the representativeness of the general population deteriorates
Solution Approach 1:
The patent creates virtual copies of diverse patient populations through AI-generated synthetic control arms that replicate the characteristics of marginalized groups. These synthetic controls are derived from real-world data and enable representation of populations that would be difficult or unethical to recruit for actual trials, thereby improving representativeness without complicating trial management.
Solution Approach 2:
The patent performs preliminary analysis of real-world data to establish baseline characteristics and outcomes for marginalized populations before the clinical trial begins. This advance preparation creates ready-to-use synthetic control groups that can be immediately applied during trial analysis, eliminating the need for complex recruitment processes while ensuring representativeness.
2Adaptability or versatility
If diverse population participation is increased, then representativeness improves, but trial complexity and logistical challenges increase
Solution Approach 1:
Instead of physically recruiting diverse participants, the patent creates virtual copies through AI-generated synthetic control arms that replicate the statistical and clinical characteristics of marginalized populations. This approach achieves representativeness without the logistical burden of recruiting, transporting, and managing diverse participant groups.
Solution Approach 2:
The patent extracts the essential characteristics of diverse populations from existing real-world data sources and isolates them into synthetic control groups. This extraction process separates the representativeness function from the physical participant recruitment process, reducing trial complexity while maintaining diversity.
3Ease of operation
If marginalized populations are excluded from trials, then trial logistics simplify, but therapeutic effectiveness in diverse groups deteriorates
Solution Approach 1:
The patent creates synthetic control arms that copy the characteristics and outcomes of marginalized populations, enabling reliable assessment of therapeutic effectiveness in these groups without requiring their physical participation. This ensures that trial results are generalizable to diverse populations while maintaining simplified logistics.
Solution Approach 2:
The patent introduces synthetic control arms as intermediaries between the actual trial participants and the marginalized populations that cannot participate. These synthetic controls mediate the assessment of therapeutic effectiveness, allowing researchers to evaluate treatment impact in diverse groups without directly enrolling difficult-to-recruit participants.
4Quantity of substance
If post-mortem tissue analysis is performed, then sample availability increases, but time sensitivity constraints increase
Solution Approach 1:
The patent performs preliminary processing and characterization of post-mortem tissue samples immediately upon receipt, establishing baseline data before degradation occurs. This advance preparation maximizes the useful information extracted from each sample while working within the narrow time window before tissue quality deteriorates.
Solution Approach 2:
The patent implements rapid processing protocols that rush through critical analysis steps within the narrow post-mortem time window. By prioritizing and accelerating key measurements and assays, the system extracts maximum value from tissue samples before degradation occurs, balancing sample availability with time sensitivity.
Data Source
AI summary
The present disclosure is directed to methods of modeling effectiveness of cancer therapeutics using live tissue from post-mortem cancer patient donors. Eligible cancer patient donors are identified and registered, along with relevant donor demographics and medical history. At least one tumor tissue sample is collected from each donor a predetermined period of time after donor death, where the tissue samples include dissociated cells and tissue sections. The samples are analyzed using one or more of in vitro, in vivo, ex vivo, and in silico models, either alone or in combination, to determine the effectiveness of at least one cancer therapeutic candidate. Donor diversity and increased sample size for tissue analysis increases the ability to identify promising therapeutic candidates relative to typical clinical trials.